SCHEMBL5536067

SCHEMBL5536067

[CH2]c1ccccc1NCc1ccccc1I

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
TAAR1 Q96RJ0 1/20 0.38
KDM1A O60341 1/20 0.38
MAPT P10636 5/20 0.38
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
MAPK1 P28482 2/20 0.37
IDO1 P14902 2/20 0.37
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539677 0.78 CA12 (0.44) CA12CA2CA9TAAR1KDM1A
SCHEMBL688010 0.78 MAPT (0.53) CA12CA2CA9MAPTALDH1A1
SCHEMBL5543785 0.78 L3MBTL1 (0.50) CA12CA2CA9MAPTALDH1A1
SCHEMBL21082313 0.78 CA12 (0.63) CA12CA2CA9MAPTALDH1A1
SCHEMBL5546124 0.74 KDM4E (0.44) MAPTALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL5540583 0.74 MAPT (0.48) CA12CA2CA9TAAR1MAPT
SCHEMBL5545750 0.74 L3MBTL1 (0.67) MAPTALDH1A1CYP2D6L3MBTL1TP53
SCHEMBL5536341 0.74 KDM4E (0.45) CA12CA2CA9ALDH1A1L3MBTL1
SCHEMBL5544340 0.74 L3MBTL1 (0.46) CA12CA2CA9MAPTALDH1A1
SCHEMBL5544368 0.74 MAPT (0.58) CA12CA2CA9MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CA12 1998/4885CA2 1853/4885CA9 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.